COS.L Regulatory News (COS)

Collagen Solutions Plc

15 December 2014 (the "Company" or " Collagen Solutions")

Commercial supply of fibrous collagen powder agreed with KYERON

for the development of a wound management device

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that its subsidiary Collagen Solutions (UK) Limited has signed an agreement with KYERON Medical Innovations (KYERON) to develop and supply fibrous collagen powder for the manufacture of a wound management device.

Collagen Solutions is committed to providing the highest quality, medical grade biomaterials to support medical devices and other products for regenerative medicine across a wide range of applications and clinical indications. Collagen Solutions will use its expanded development capability in the UK, US and New Zealand to develop a specific grade of fibrous collagen powder which KYERON will then formulate into a product for commercialization in the growing wound management market.

KYERON was formed in 2007 and is a private Dutch biomaterials company based in Enschede, the Netherlands, specialising in developing solutions to medical needs. Its products use the innovative biomaterial knowledge of the Company to produce a range of products for various orthopaedic, neurosurgical and periodontal tissue grafting procedures.

Dr Stewart White, Chief Executive Officer of Collagen Solutions said, "This agreement to provide our medical grade fibrous collagen is an excellent example of how we now bring together our development capability and world-recognised expertise in the manufacture of medical grade collagen products. We are capable of providing clients with a product that meets their needs precisely. We are pleased to see that KYERON has the confidence in the capabilities of Collagen Solutions to identify and manufacture consistently and in sufficient quantity, collagen products to satisfy their commercial needs as demand for their products grow. More importantly, we can support KYERON with respect to regulatory submissions for new products containing our collagen."

Chief Executive Officer of KYERON, Mr. Ronny Masselink said, "We are a manufacturer of innovative products using the best available raw materials. This is a great opportunity for us to work closely with a collagen specialist that can provide us with the highest grade materials consistently. Collagen Solutions will be our partner in the development of a fibrous collagen powder to benefit those patients suffering acute and chronic wounds. We see Collagen Solutions as our preferred supplier for these raw materials for this and other collagen-based biomaterials such as bone graft substitutes. Working with them we now have access to the required state-of-art collagen technology to create our next generation of innovative products."

Enquiries: